Therefore, it might be difficult for elafibranor to form stable complexes with any of the PPAR subtypes, especially with PPARδ/γ, and to induce enough clinical impact in some cases (e.g., NASH). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.